By Adriano Marchese Bellus Health Inc. s Toronto-listed shares doubled Tuesday morning after the company agreed to sell itself to British pharmaceutical and biotechnology giant GSK PLC for $2. | April 18, 2023
By Colin Kellaher Shares of Bellus Health Inc. nearly doubled in premarket trading Tuesday after the late-clinical-stage biopharmaceutical company agreed to be acquired by U.K. drug major GSK. | April 18, 2023
BELLUS Health Inc. announced positive data from its Phase 1 bioavailability equivalence study evaluating a once-daily Extended-Release formulation of camlipixant in comparison to a twice-daily. | April 6, 2023
Once-daily Extended-Release formulation demonstrated equivalent bioavailability to twice-daily Immediate Release formulation
Extended-Release formulation was well tolerated, with the safety profile. | April 5, 2023
NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE is hereby given that the annual and special meeting of the common shareholders of BELLUS Health Inc. will be held. | March 30, 2023